ИСТИНА

The oxidative stress is considered to be involved in the pathogenesis of many diseases and there is strong evidence that the antioxidants prevent some pathologies including cancer. The specific chemical properties of metal-based drugs containing functional groups with redox and antioxidant activity impart innovative pharmacological profiles to this type of therapeutic agents [1]. The electrochemical, anti/prooxidant activity and cytotoxicity studies of novel organometallic/coordination compounds (ferrocenes, complexes with di-(2-picolyl)amine ligand, porphyrins, pyridines, thiols, carboxylates) based on either biogenic metals (Fe, Mn, Co, Cu, Zn, Ni) or exogenic metals (Sn, Au) were studied [2-4]. In order to assess the overall antioxidant efficiency of such multifunctional compounds, a networked system of methods including a series of rapid tests, electrochemical studies, model reactions and biological testing was applied (Scheme 1).' Scheme 1 The data obtained demonstrate that combining of two redox active centers (metal ion and redox active organic ligand with antioxidant function) is a promising approach to find the novel hybrid therapeutic agents with opposed biological mode of action which can be advantageous over drugs based on metal or organic compound only. References 1. Milaeva, E., Tyurin, V. Pure&Appl.Chem. 2017, 89, 1065. 2. Shpakovsky, D. et al. Metallomics, 2018, 10, 406. 3. Milaeva, E., Tyurin V., et al. J.Organomet.Chem. 2017, 839, 60. 4. Tyurin, V., Moiseeva, A., Shpakovsky, D., Milaeva, E. J. Electroanal. Chem. 2015, 756, 212. Acknowlements: the financial support of RFBR 17-03-00892 and 18-03-00203 is gratefully acknowledged.